Angle rumours and further Director buys at Avanti

It's been a fairly quiet week regarding news stories for shares that I hold, but considerable excitement was generated by a story in 'The Times' on Tuesday, suggesting that potential suitors were circling Angle with the possibility of making an offer(s) in the region of £2 plus.

http://www.thetimes.co.uk/tto/business/columnists/article3871158.ece

"London’s “hot money”, those fast chaps who hunt lucrative takeovers, think they have found an angle.
Angle plc is a small, AIM-quoted, biotechnology company that largely flies under the radar. However, there were whispers yesterday that it had been tapped up, so far informally, by more than one potential bidder. No names were mentioned, but any number of bigger healthcare players may be interested.
As well as specialising in foetal health, Angle owns a subsidiary, Parsortix, which has developed a clever technique to separate blood cells to test for cancer and which already has a patent in America. Angle bulls expect Parsortix to be granted regulatory approval there by the middle of next year, about six months after it receives the green light in Europe.
Though the shares edged a ha’penny lower to 73p yesterday, they have jumped by nearly 25 per cent since the start of this month. At about the same time, trading volumes, the number of shares changing hands, also spiked, itself often a signal that something may be afoot.
The rumoured price that potential buyers have indicated they may be prepared to pay is above 200p, still some distance north of where Angle shares are trading now."

The share price currently stands at 81p. I mentioned Angle as one of my speculative buys back in December 2012, and certainly it appears to be paying off handsomely at the moment.

http://michae1mouse.blogspot.co.uk/2012/12/a-new-angle.html

It seems highly unlikely that the Times would publish the above article without some reliable information, and the company's silence since the article was published appears to speak volumes. Whilst £2+ would be a massive premium to my 27p purchase price, the greedy part of me says that if big healthcare players are prepared to pay £2+ now, what would Angle be worth in a few years time. Many, many multiples of this I expect. However, this assumes that the product will be a raging success and that Angle have the wherewithal and clout to bring shareholders maximum returns by going it alone. Also, regulatory approvals have not been won just yet and validation of the Parsortix device's capabilities are still being awaited from the Paterson Institute.

If the rumours are true, it is a difficult decision for Angle's Directors. Either way it is beginning to look like shareholders will be richly rewarded, although "never count your chickens", as they say.

In other news I noticed that there was a further Director purchase at Avanti Communications on Friday where John Brackenbury, Chairman, bought a further £85,000 worth. The share price has risen well above it's recent lows, but if the company can retain momentum then the shares still have considerable upside potential.